The safety of albiglutide for the treatment of type 2 diabetes

References

• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–1439.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–165.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Asa S. Glucagon gene expression in vertebrate brain. J Biol Chem. 1988;263:13475–13478.
   PubMed Web of Science ®Google Scholar
• Jin SL, Han VK, Simmons JG, et al. Distribution of glucagonlike peptide I (GLP-I), glucagon, glicentin in the rat brain: an immunocytochemical study. J Comp Neurol. 1988;271:519–532.
   PubMed Web of Science ®Google Scholar
• Larsen PJ, Tang-Christensen M, Holst JJ, et al. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience. 1977;77:257–270.
   Web of Science ®Google Scholar
• Larsen PJ, Holst JJ. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept. 2005;128:97–107.
   PubMedGoogle Scholar
• Mentlein R1, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214:829–835.
   PubMedGoogle Scholar
• Gautier J, Fetita S, Sobngwi E, et al. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab. 2005;31:233–242.
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass. Diabetes Technol Ther. 2005;7:651–657.
   PubMedGoogle Scholar
• Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80:952–957.
   PubMed Web of Science ®Google Scholar
• Deacon CF, Pridal L, Klarskov L, et al. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol Endocrinol Metab. 1996;271:E458–E464.
   PubMed Web of Science ®Google Scholar
• Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46–52.
   PubMed Web of Science ®Google Scholar
• Mari A, Bagger JI, Ferrannini E, et al. Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes. PLoS One. 2013 Sep 3;8(9):e73154.
   PubMed Web of Science ®Google Scholar
• Harris KB. Boland CL Adjunctive role of glucagon-like peptide-1 receptor agonists in the management of type 1 diabetes mellitus. Pharmacotherapy. 2016 Sep;36(9):1011–1020.
   PubMed Web of Science ®Google Scholar
• Tella SH, Rendell MS. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Ther Adv Endocrinol Metab. 2015;63:109–134.
   Web of Science ®Google Scholar
• Neumiller J, Campbell R. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 di-abetes mellitus. Ann Pharmacother. 2009;43:1433–1444.
   PubMed Web of Science ®Google Scholar
• Norris S, Lee N, Thakurta S, et al. Exenatide efficacy and safety: a systematic review. Diabet Med. 2009;26:837–846.
   PubMed Web of Science ®Google Scholar
• Petersen A, Christensen M. Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2013;6:217–231.
   PubMedGoogle Scholar
• Trujillo J, Nuffer W. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother. 2014;48:1494–1501.
   PubMed Web of Science ®Google Scholar
• Gurung T, Shyangdan DS, O’Hare JP, et al. A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide. Diabetes Metab Syndr Obes. 2015;8:363–386.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Balas B, Charbonnel B, et al. T-emerge 2 Study Group. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care. 2013;36:498–504.
   PubMed Web of Science ®Google Scholar
• Green BD, Gault VA, Irwin N, et al. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1. Biol Chem. 2003;384:1543–1551.
   PubMed Web of Science ®Google Scholar
• Turton MD, O’Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379:69–72.
   PubMed Web of Science ®Google Scholar
• Steinert RE, Schirra J, Meyer-Gerspach AC, et al. Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men. Am J Clin Nutr. 2014;100:514–523.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014;124:4223–4226.
   PubMed Web of Science ®Google Scholar
• Gedulin BR, Nikoulina SE, Smith PA, et al. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology. 2005;146:2069–2076.
   PubMed Web of Science ®Google Scholar
• Umapathysivam MM, Lee MY, Jones KL, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014;63:785–790.
   PubMed Web of Science ®Google Scholar
• Lorenz M, Pfeiffer C, Steinsträsser A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes–relationship to postprandial glycemia. Regul Pept. 2013;185:1–8.
   PubMedGoogle Scholar
• Astrup A, Carraro R, Finer N, et al. NN8022–1807 investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36:843–854.
   PubMed Web of Science ®Google Scholar
• Lean M, Carraro R, Finer N, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes. 2014;38:689–697.
   PubMed Web of Science ®Google Scholar
• Bush MA, Matthews JE, de Boever EH, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab. 2009;11:498–505.
   PubMed Web of Science ®Google Scholar
• Matthews JE, Stewart MW, de Boever EH, et al. Pharmacodynamics, pharmacoki-netics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrin & Metab. 2008;93:4810–4817.
   PubMed Web of Science ®Google Scholar
• Young MA, Wald JA, Matthews JE, et al. Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. Postgrad Med. 2014;126:84–97.
   PubMed Web of Science ®Google Scholar
• Cho YM. Incretin physiology and pathophysiology from an Asian perspective. J Diabetes Investig. 2015;6:495–507.
   PubMed Web of Science ®Google Scholar
• Oh TJ, Kim MY, Shin JY, et al. The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes. Clin Endocrinol (Oxf). 2014;80:221–227.
   PubMed Web of Science ®Google Scholar
• Hompesch M, Jones-Leone A, Carr MC, et al. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:82–90.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report, Eperzan, International non-proprietary name: albiglutide, Procedure No. EMEA/H/C/002735/0000 23 January 2014 EMA/CHMP/705417/2013 Committee for Medicinal Products for Human Use (CHMP)
   Google Scholar
• Drug Approval Package. FDA Tanzeum (Albiglutide) Injection Company: GlaxoSmithKline LLC Application No.: 125431 Approval Date: Apr 15 2014.
   Google Scholar
• Reusch J, Stewart M, Perkins C, et al. Efficacy and safety of once weekly GLP-1 receptor agonist albiglutide (HARMONY 1): 52 week primary endpoint results from a randomized, double-blind, placebo controlled, trial in patients with type 2 diabetes mellitus not controlled on pioglitazone ± metformin. Diabetes Obes Metab. 2014;16:1257–1264.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Stewart MW, Perkins C, et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia. 2016;59:266–274.
   PubMed Web of Science ®Google Scholar
• HARMONY 3 Study Group; Ahrén B, Johnson SL, Stewart M, et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37:2141–2148.
   PubMed Web of Science ®Google Scholar
• Weissman PN, Carr MC, Ye J, et al. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia. 2014;57:2475–2484.
   PubMed Web of Science ®Google Scholar
• Home PD, Shamanna P, Stewart M, et al. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes Metab. 2015;17:179–187.
   PubMed Web of Science ®Google Scholar
• Harmony 6 Study Group; Rosenstock J, Fonseca VA, Gross JL, et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care. 2014;37:2317–2325.
   PubMed Web of Science ®Google Scholar
• HARMONY 7 study group; Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289–297.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Carr MC, Stewart M, et al. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014;37:2723–2730.
   PubMed Web of Science ®Google Scholar
• Seino Y, Nakajima H, Miyahara H, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin. 2009 Dec;25(12):3049–3057.
   PubMed Web of Science ®Google Scholar
• Seino Y, Inagaki N, Miyahara H, et al. A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus. Curr Med Res Opin. 2014 Jun;30(6):105–106.
   Web of Science ®Google Scholar
• Ahrén B, Carr MC, Murphy K, et al. Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Res Clin Pract. 2017;126:230–239.
   PubMed Web of Science ®Google Scholar
• Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150–156.
   PubMed Web of Science ®Google Scholar
• Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs — FDA and EMA assessment. N Engl J Med. 2014;370:794–797.
   PubMed Web of Science ®Google Scholar
• Fisher M, Petrie MC, Ambery PD, et al. Cardiovascular safety of albiglutide in the harmony programme: a meta-analysis. Lancet Diabetes Endocrinol. 2015;3:697–703.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016;39:222–230.
   PubMed Web of Science ®Google Scholar
• Ten Kulve JS, Dj V, van Bloemendaal L, et al. Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption. J Endocrinol. 2016;229:1–12.
   PubMed Web of Science ®Google Scholar
• Ten Kulve JS, Veltman DJ, van Bloemendaal L, et al. IJzerman RG. Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. Diabetologia. 2015;58:2688–2698.
   PubMed Web of Science ®Google Scholar
• Richard JE, Anderberg RH, Göteson A, et al. Activation of the GLP-1 receptors in the nucleus of the solitary tract reduces food reward behavior and targets the mesolimbic system. PLoS One. 2015;10:e0119034.
   PubMed Web of Science ®Google Scholar
• Hottenstein CS, Szapacs ME, Maier CC Investigation of blood-brain barrier penetration of albiglutide in mice. Abstract 1044P presented at American Diabetes Association Annual Meeting, New Orleans, Louisiana, June 11, 2016
   Google Scholar
• Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists diabetes. Obesity and Metabolism. 2016;18:317–332.
   Web of Science ®Google Scholar
• Bettge K, Kahle M, Abd El Aziz MS, et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes Metab. 2017 Mar;19(3):336–347.
   PubMed Web of Science ®Google Scholar
• ELIXA Investigators; Bentley-Lewis R, Aguilar D, Riddle MC, et al. Rationale, design, and evaluation of LIXisenatide in acute coronary syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J. 2015;169:631–638.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al., EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Rendell M. The path to approval of new drugs for diabetes. Expert Opin Drug Saf. 2013;12:195–207.
   PubMed Web of Science ®Google Scholar